Latest Administration News

5E Advanced Materials reports progress on its California boron project with a new feasibility study and equity raises, while highlighting ongoing funding uncertainties.

FleetPartners Group Limited reported a 3.2% revenue increase to $786.2 million for FY2025, despite a 3.3% decline in net profit after tax to $75.3 million. The company completed its Accelerate program, delivering $6 million in annualised cost savings and declared a final unfranked dividend of 13.6 cents per share.

Equity Trustees Limited announces an off-market buy-back offer for MA Credit Income Trust units, allowing eligible unitholders to sell up to 5% of total units at net asset value as of 31 December 2025.

Sarama Resources Ltd reported a $1.9 million loss for the first nine months of 2025 while securing A$2.7 million in equity funding and advancing a $242 million arbitration claim against Burkina Faso over mining permit expropriation.

Capricorn Metals Ltd has officially completed its acquisition of Warriedar Resources Limited through a court-approved scheme of arrangement, marking a significant consolidation in the gold mining sector.

Biotron Limited’s lead HBV drug BIT-HBV001 demonstrates superior antiviral activity and synergy with the current standard treatment Tenofovir in preclinical models, advancing hopes for a more effective Hepatitis B therapy.

Trigg Minerals has expanded its Tennessee Mountain Tungsten Project in Nevada by acquiring contiguous claims that consolidate a district-scale mineralised system, setting the stage for modern exploration and resource definition.

Besra Gold Inc. reported a $3.47 million loss for Q1 2026, weighed down by finance costs tied to a major gold purchase agreement. Despite asset impairments and net liabilities, management remains cautiously optimistic about ongoing funding and project development.

PYC Therapeutics reports sustained vision improvements in patients with Retinitis Pigmentosa type 11 treated with VP-001, showing promising safety and efficacy up to 18 months. The company plans to engage the FDA in early 2026 to finalize pivotal trial design.

Island Pharmaceuticals will host a webinar to discuss the FDA's feedback on the clinical development and regulatory approval of its antiviral drug Galidesivir, including key considerations under the FDA's Animal Rule and Priority Review Voucher eligibility.

EBOS Group Limited has updated its Dividend Reinvestment Plan rules, offering shareholders new ways to reinvest dividends into additional shares. The changes, effective immediately, provide greater flexibility and maintain board discretion over share issuance terms.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.